Abbott receives FDA clearance for CardioMEMS HF System updates enabling home pressure monitoring via smartphone app

Abbott announced that the U.S. Food and Drug Administration has cleared updated software for its CardioMEMS HF System. The changes add a patient facing component through the CardioGuide HF mobile application.

The new functionality lets individuals with the implanted pulmonary artery pressure sensor view their readings directly on a smartphone. By seeing pressure trends at home, patients can become more engaged in managing heart-failure symptoms that often develop before they are felt.

Clinicians have used CardioMEMS data for more than a decade to guide therapy, and the FDA clearance expands the system’s role in personalized care. The move reflects a broader industry push toward remote monitoring and digital health tools.